• Hyundai Mobis and its global partners have formed a global alliance for Holographic Windshield Display (HWD)
• The alliance combines capabilities in systems (Hyundai Mobis), optics (ZEISS), film (tesa), and automotive glass (Sekurit), targeting mass production starting by 2029
• HWD utilizes the vehicle’s front windshield as a giant display, separating driver and passenger screens to ensure both safety and convenience

SEOUL, South Korea, Feb. 3, 2026 /PRNewswire/ — Hyundai Mobis (KRX 012330) has partnered with global leading companies to secure the next-generation vehicle display market. Hyundai Mobis announced on the 3rd the launch of the “Quad Alliance” with European specialist companies, each possessing leading technologies in their respective fields, for the mass production of Holographic Windshield Displays (HWD).

This technology development alliance includes Germany’s ZEISS, which possesses world-class optical technology; Germany’s tesa, a global leading company in tape adhesion; and France’s Saint-Gobain Sekurit, Europe’s top automotive glass manufacturer, joining forces with Hyundai Mobis. Hyundai Mobis plans to expand the collaborative ecosystem to four companies and pursue the actual commercialization of HWD by 2029.

The Holographic Windshield Display (HWD) is an innovative technology that utilizes the vehicle’s front windshield as a massive display without a separate physical screen, enabling drivers to view driving information without distracting their gaze. Its key advantage lies in precisely projecting diverse driving information and infotainment images onto the eye level of the driver and passenger using a special ‘Holographic Optical Element (HOE)’ film laminated within the windshield glass.

HWD employs holographic optical element(HOE) with a transmittance of 92% or higher (clear glass level) and an overwhelming brightness exceeding 10,000 nits (twice the level of outdoor LED billboards), providing clear image quality even in bright daylight environments. Furthermore, leveraging the precise light redirection feature of HOE, the system is designed to prevent the driver from viewing the passenger-side screen. This allows the passenger to safely enjoy various infotainment features like video viewing and gaming even while driving. This technology maximizes driving safety and space utilization, and is expected to emerge as a core technology for future mobility.

Through this four-party alliance, Hyundai Mobis will oversee the system design and integration of the overall HWD system and the image-projecting projector, leveraging its expertise in vehicle interface solutions. ZEISS will handle the optical design and master development of the HOE film, while tesa will ensure reliable and precise mass replication of holographic films. Sekurit will handle the precision process of bonding the film to the windshield glass.

This technology collaboration signifies the establishment of a ‘one-stop supply chain solution’ encompassing everything from HWD’s optical design to HOE replication and system assembly. Hyundai Mobis’ strategy is to secure both mass-production quality and reliability by proactively establishing a supply chain ecosystem, on top of its leading technological capabilities.

Meanwhile, Hyundai Mobis has garnered significant interest from major customers by successively unveiling advanced models featuring this technology at global exhibitions including CES, the German IAA, and the Shanghai Motor Show. Notably, at CES 2026 held in the US last month, it won an Innovation Award, once again proving its technological competitiveness.

“Through this core technology that unlocks the future of automotive displays, we will provide differentiated value to our customers,” said Jung Soo-kyung, Executive Vice President and Head of the Automotive Electronics Business Unit at Hyundai Mobis. “We will closely collaborate with global partners through the mass production phase to maximize our technological competitiveness and firmly establish our image as a leader in innovative technology in the global market.”

About Hyundai Mobis

Hyundai Mobis is a leading global automotive supplier delivering mobility solutions across core components—including electronic control, electrification, automotive semiconductors, braking, chassis, and steering.

Focusing on autonomous driving, connectivity, and electrification, the company integrates software and hardware to advance smart mobility. Backed by an R&D headquarters in Korea and technology centers in the United States, Germany, China, and India, Hyundai Mobis supports customers worldwide. Building on its R&D and manufacturing capabilities, the company is expanding into future mobility domains such as robotics. For more information, please visit http://www.mobis.com.

Media Contact 
Choon Kee Hwang : ckhwang@mobis.com
Jihyun Han : jihyun.han@mobis.com

• Maximizing large-scale AI model optimization performance on FuriosaAI’s NPU ‘RNGD’ by supplying the AI compression and optimization platform ‘NetsPresso®’
• Expanding technology supply from mobile and automotive to AI server infrastructure
• Preparing to scale global business with a packaged solution combining Nota Vision Agent (NVA) and FuriosaAI’s NPU

SEOUL, South Korea, Feb. 3, 2026 /PRNewswire/ — Nota AI (CEO Myungsu Chae), a company specializing in AI model compression and optimization, announced that it has signed a technology supply contract to provide its AI model optimization platform, ‘NetsPresso®,’ for FuriosaAI’s flagship chip, ‘RNGD (pronounced “Renegade”).

This contract signifies that NetsPresso® has established itself as an essential technology not only for low-spec devices but also in the high-performance computing infrastructure sector. NetsPresso® is a platform that reduces AI model sizes by up to 90% while maintaining accuracy, enabling efficient optimization and deployment of AI models tailored to specific hardware specifications.

Through this agreement, Nota AI’s advanced optimization technology will be utilized to enhance the inference performance of RNGD, ensuring rapid and stable operation of large-scale AI models. Notably, this collaboration allows Nota AI to broaden its supply range beyond mobile, PC, and automotive APs into the AI server and data center semiconductor sectors, effectively expanding its influence across the entire AI optimization market.

In addition to the supply contract, the two companies have agreed to establish a strategic partnership based on ‘Nota Vision Agent (NVA),’ Nota AI’s vision AI solution. By introducing a packaged solution that combines Nota AI’s NVA with FuriosaAI’s RNGD, the companies have laid the groundwork for a substantial and concrete business cooperation system designed to accelerate revenue growth. Following a technical cooperation MOU in November and the current definitive supply contract, this latest partnership for a joint business model solidifies a close collaboration spanning from R&D to commrcialization.

FuriosaAI expects to increase the utility and competitiveness of its NPU products across a wide range of industrial sites by leveraging Nota AI’s optimization solutions. Similarly, Nota AI plans to secure new business opportunities in various industrial sectors, including physical AI, by supplying high-performance, lightweight AI models in a package integrated with FuriosaAI’s NPU.

“This contract is a result of NetsPresso®’s optimization technology expanding beyond on-device environments like mobile and mobility into high-performance data centers, proving its commercial value once again,” said Myungsu Chae, CEO of Nota AI. “As a strategic partner of FuriosaAI, we will continue to demonstrate the prowess of Korea’s AI technology in the global market.”

June Paik, CEO of FuriosaAI, stated, “The combination of FuriosaAI’s innovative NPU technology and Nota AI’s sophisticated optimization capabilities represents a meaningful step in demonstrating the global competitiveness of Korea’s AI innovation. Through close technical collaboration with Nota AI, we will showcase solutions that provide overwhelming performance and efficiency in real-world industrial settings.”

• BioDlink has successfully implemented Veeva QMS, marking a key milestone in its digital transformation and strengthening its GMP quality management capabilities.
• It enables a standardized, data-driven quality framework, supporting compliance, efficiency, and long-term continuous improvement for global partners.

SUZHOU, China, Feb. 3, 2026 /PRNewswire/ — BioDlink today announced the successful go-live of Veeva QMS, marking a key milestone in the company’s quality digitalization strategy. The system officially entered operation following a launch event held on January 29 with representatives from Veeva and the joint project team.

BioDlink places quality management and regulatory compliance at the core of its operations. By implementing Veeva QMS, a globally recognized platform adopted across the life sciences industry, BioDlink aims to enhance the efficiency, accuracy, and compliance of its GMP-compliant manufacturing and quality processes, supporting global partners in the development and commercialization of innovative therapies.

The initial deployment covers four core quality processes: Deviation Management, Change Management, Laboratory Investigation, and Corrective and Preventive Action (CAPA) Management. This implementation establishes a digital, standardized, and end-to-end quality operations framework. Additional modules, including Quality Risk Management, Audit Management, Supplier Management, Annual Product Quality Review, and Management Review, are planned for future phases to further strengthen the company’s quality system.

Veeva QMS is a cloud-based quality management system purpose-built for the life sciences industry, designed to help organizations address complex regulatory requirements and the growing demands of modern quality management. Today, more than 300 companies worldwide streamline quality processes with Veeva QMS, including 17 of the Top 20 global pharmas.    

Dr. Jian Zhang, Acting CEO of BioDlink, said, “The go-live of QMS marks the new start of a new lifecycle for our quality system. Beyond digitizing paper-based processes, it represents a fundamental transformation of our quality management model, enabling structured data management, knowledge capture, and continuous quality improvement. We will continue to advance our digital roadmap, including the phased implementation of electronic batch records, toward comprehensive GMP digitalization.”

Juliana Lu, Sr. Director, China Quality Strategy, Veeva Systems, commented, “We are honored to support BioDlink’s quality digitalization and global strategy. For a CDMO, quality is not only the cornerstone of compliance but also a core asset for building trust and competitive differentiation. Veeva is committed to helping BioDlink establish a single source of truth digital foundation through our QMS solution built on a unified Quality Cloud. This ensures global compliance while significantly enhancing process efficiency, transparency, and internal and external collaboration. We look forward to deepening our partnership to drive operational excellence and transformative quality management across the industry.”                         

The implementation further strengthens BioDlink’s quality and compliance capabilities while delivering a transparent, end-to-end digital quality platform to support global biopharmaceutical partners and accelerate the delivery of innovative therapies worldwide.

About BioDlink

BioDlink, a leading global Contract Development and Manufacturing Organization (CDMO) specializing in biologics, is committed to being the trusted partner of choice for biopharmaceutical innovators worldwide. Leveraging our advanced one-base integrated platform, BioDlink delivers end-to-end CDMO services for protein-based therapeutics (such as mAb, BsAb), biosimilar, and bioconjugated drugs (such as XDCs/ADCs) from early-stage research through to commercial-scale manufacturing.

BioDlink operates large-scale biopharmaceutical manufacturing facilities compliant with GMP standards and adheres to international quality management systems aligned with regulatory requirements in the US, the EU, and China. With our cutting-edge technology platforms and expert teams, BioDlink facilitates accelerated development timelines, with clients spanning Europe, the Americas, Asia, and several key emerging markets.

BioDlink operates with a clear service philosophy: “Quality-Driven, Innovation-Enabled, Growth-Shared,” and has assembled an experienced and forward-thinking team. Committed to rigorous quality and compliance, the company nurtures a collaborative ecosystem that empowers its partners and delivers shared success. For more information, please visit: https://biodlink.com/  

About Veeva Systems

Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.

In China, Veeva provides end-to-end cloud solutions spanning the entire life sciences lifecycle—from R&D and manufacturing to commercialization—and is dedicated to building the industry cloud for the Chinese life sciences sector. Veeva is headquartered in the San Francisco Bay Area, with offices across Europe, Asia, and Latin America.

OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ — The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufacturing preparedness for future epidemic and pandemic threats. The collaboration will see Samsung Biologics join CEPI’s Vaccine Manufacturing Facility Network (VMFN) with the aim of accelerating the availability of protein-based vaccines and advancing equitable access to those vaccines during future outbreaks in Low- and Middle-Income Countries (LMICs).

Supported by an initial budget of up to US$20 million, CEPI will work with Samsung Biologics to establish a scalable, rapid manufacturing process for recombinant-protein vaccines. This will include leveraging Samsung Biologics’ well-established mammalian cell-based infrastructure — a flexible system that plays a key role in manufacturing protein-based products efficiently and at a very large scale — and its mature quality and regulatory systems. The aim is to pre-position a ready-to-activate process that can be deployed quickly when a new viral threat emerges, giving protein-based vaccines a rapid response capability in future.

Under the agreement, Samsung Biologics will also conduct a simulated outbreak response exercise using a wild-type H5 influenza as a prototype pathogen recommended by the WHO. The exercise is designed to demonstrate the speed and robustness of Samsung Biologics’ end-to-end capabilities, from antigen development through to vaccine drug product manufacture to supply. This simulation will provide insights into how quickly recombinant-protein vaccines can be manufactured at scale in an outbreak scenario and help lay the grounds to prepare a generic regulatory submission dossier.

By joining CEPI’s global VMFN, in a future pandemic situation, Samsung Biologics will provide CEPI with guaranteed access to up to potentially 50 million vaccine doses, and an additional one billion doses of drug substance ready to be converted into finished vaccines. This arrangement reserves doses for vulnerable populations in underserved LMIC regions and at the same time, enables Korea’s national needs to be met in line with CEPI’s Equitable Access Policy.

“We are delighted to welcome Samsung Biologics to CEPI’s Vaccine Manufacturing Facility Network. Their recombinant protein production scale and technical capabilities add vital strength to our outbreak-response infrastructure,” said Dr Richard Hatchett, CEO of CEPI. “Partnering with one of the world’s foremost recombinant protein contract manufacturers will help us move more rapidly from prototype sequence to production and get vaccines to the underserved global communities that need them most.”

The partnership supports CEPI’s 100 Days Mission — a global effort to develop vaccines within 100 days of identifying a novel pathogen with pandemic potential — by putting in place pre-agreed, end-to-end manufacturing pathways that enable rapid scaling. It also advances CEPI’s strategy to broaden the technological mix and geographical reach of the VMFN with our first East Asian partner – helping to ensure more agile, distributed, and reliable supply during future disease outbreaks.

“This agreement reflects our commitment to supporting a reliable and agile vaccine supply ecosystem through continued innovation and strong collaboration. It also contributes to Korea’s ability to secure timely access to vaccines during urgent public-health situations,” said John Rim, President and CEO of Samsung Biologics. “By working with CEPI to advance recombinant protein vaccine development and ensure capacity for timely production when demand rises, we aim to broaden access to high-quality vaccines for patients around the world. Samsung Biologics will continue to apply its technical and manufacturing expertise to strengthen global preparedness and help build a more resilient response environment.”

Additional projects to support vaccine technology transfer, regulatory preparedness, and developing vaccine innovations may be developed as the partnership with Samsung Biologics evolves. Samsung Biologics advanced large-scale GMP manufacturing capabilities will ensure reliable access to vaccine production capacity, thereby supporting effective responses for future epidemics and pandemics.

Samsung Biologics becomes the latest organisation to join CEPI’s growing VMFN, which now includes manufacturing partners in Brazil, India, Indonesia, South Africa and Senegal. Together, the VMFN aims to create a globally distributed manufacturing ecosystem capable of producing vaccines at speed and scale — ensuring that populations everywhere, but particularly in LMIC regions, can access countermeasures when new health threats emerge.

Notes to editors

CEPI is an innovative partnership between public, private, philanthropic, and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 70 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI’s pandemic-beating plan is the ‘100 Days Mission’ to compress the time taken to develop safe, effective and accessible vaccines against new threats to just 100 days. Learn more at CEPI.net.  

About Samsung Biologics 

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 liters from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region.

Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.

For more information, visit https://samsungbiologics.com/

Media contacts

CEPI
E: press@cepi.net
P: +44 7387 055214

Samsung Biologics  
Claire Kim, Senior Director cair.kim@samsung.com

SEOUL, South Korea, Feb. 3, 2026 /PRNewswire/ — Carat AI, a global AI platform serving over 3 million users, today announced the launch of its Agent App Store. This milestone marks Carat’s evolution from a simple content tool into a workforce platform that provides users with “AI Content Creators”—virtual partners capable of handling complex production workflows.

Hire an AI Creator, Not Just a Tool

While platforms like Higgsfield and Freepik excel at generating high-quality individual assets, they often remain “tools” that require users to manually stitch together the creative process. Carat AI empowers everyday users to bypass these technical complexities. By orchestrating a vast and expanding library of top-tier multimodal models behind the scenes, Carat allows users to automate the entire creative workflow—from planning and scriptwriting to generation and editing.

The Mini Agent Ecosystem: From Concept to Expert Execution

The core of the new App Store is the “Mini Agent” system. Unlike simple pre-trained models, these agents are sophisticated workflows built upon expert guidelines and skills. This approach is already transforming productivity:

• For Business: A small business owner can now produce TV-grade commercials without hiring an ad agency.
• For Creators: Individual influencers can condense a week’s worth of editing and scripting into a single afternoon.

Consistency Through Memory

Supporting the agent ecosystem is Carat’s Contextual Memory Core. Unlike most content generation tools that treat every prompt as a new task, Carat’s agents remember project details, user preferences, and frequently used assets. This allows for long-term consistency, simulating the experience of working with a dedicated human partner.

“Most people have great ideas but lack the technical skills to execute them professionally,” said Jinuk Jang, CEO of Carat AI. “Our Agent App Store removes that barrier by providing AI partners that handle the entire production process.”

Frequently Asked Questions

Q: What is Carat AI?

A: Carat AI is a leading AI agent platform that empowers anyone to create professional-grade images, videos, and music through simple conversation. By “hiring” specialized Mini Agents, users can bypass technical barriers and automate complex creative workflows.

Q: What can I create with Carat AI?

A: You can generate high-quality 4K images, cinematic videos, AI voices, and even original songs. Whether it’s for social media content, business commercials, or personal projects, Carat AI acts as an all-in-one digital production studio.

Q: Is Carat AI free to use?

A: Yes. Carat AI offers a free plan where users receive daily credits to explore image, video, and audio generation at no cost. For professional creators and businesses requiring higher volume and advanced features, premium plans are available starting at $20.

Q: Who are the primary users of Carat AI?

A: Our platform is trusted by over 3 million users worldwide, including top-tier influencers, content creators, and small business owners. These professionals use Carat AI to produce high-end content that typically requires a full production team.

Q: How can I access the Agent App Store?

A: You can start creating immediately by visiting the Agent App Store at https://carat.im/en, available on Web, iOS, and Android.

About Carat AI

Carat AI is a leading AI agent platform serving over 3 million users across 160+ countries, including the US, UK, Korea, and Japan. By orchestrating cutting-edge models into an all-in-one ecosystem, Carat empowers users to create professional images, videos, and audio through simple conversation. Carat bypasses technical barriers, providing AI agents that act as skilled virtual employees for creators and businesses.

Follow:

• YouTube: https://www.youtube.com/@carat_ai
• Instagram: https://www.instagram.com/carat.app
• LinkedIn: https://www.linkedin.com/company/carat-ai

Media Contact:

Carat AI Team
contact@carat.im
https://carat.im

NEW YORK, Feb. 3, 2026 /PRNewswire/ — Plume, the global leading real-world asset (RWA) network, has introduced the KRW-denominated stablecoin KRW1 issued by leading digital asset custody firm BDACS (Beyond Digital Asset Custody Service).

Through this collaboration, Korean investors and institutions gain the foundation to make payments and investments directly in Korean won (via KRW1) across Plume’s ecosystem.

“Plume currently operates one of the world’s largest RWA ecosystems, with more than 280,000 RWA holders and $645 million in RWAs. By adding KRW1 as a payment and investment instrument, we are opening a new pathway, particularly for Korean institutional investors, to enter the RWA market using a non-USD currency,” said Teddy Pornprinya, Co-Founder and Chief Business Officer (CBO) of Plume.

Plume’s decision to select the Korean won as its first non-USD currency reflects Korea’s regulatory readiness and institutional demand. Following amendments to the Capital Markets Act and the Electronic Securities Act last year, Korea introduced a tokenized securities (STO) framework that brings security tokens into the regulated financial system, and is regarded as having one of the more advanced RWA regulatory environments in Asia.

“Korea is a market where regulation is relatively clear yet supportive of innovation. Major financial institutions are expanding investments related to RWAs and blockchain, making Korea a key strategic hub for Plume’s expansion in Asia,” said Pornprinya.

Launched by BDACS in September 2025, KRW1 is fully backed by KRW deposits held in an escrow account at a domestic commercial bank, Woori Bank. BDACS has successfully completed a proof of concept (PoC covering KRW deposits, token issuance, and on-chain verification), validating both technical feasibility and operational stability.

“Plume has established itself as an institution-ready RWA platform through embedded compliance and full EVM compatibility,” said Hong-yeol Ryu, CEO of BDACS. “The integration of KRW1 further strengthens its position as a regulation-aligned RWA infrastructure provider in Asia.”

Plume opens access to assets from global asset managers including Apollo Global Management, WisdomTree, and BlackOpal, spanning asset classes such as real-estate-backed loans, private funds, and government bonds.

With the introduction of KRW1, Korean investors can invest and receive returns directly in won, reducing FX costs and operational complexity, while paving the way for greater institutional participation, future on-chain issuance by Korean financial institutions, and expansion to additional Asian currencies such as the Japanese yen and Singapore dollar.

About Plume

Plume is the leading real-world asset (RWA) network. It enables asset issuers and institutions to deploy onchain assets through its native infrastructure and grow those assets through its flagship real-world yield protocol Nest. As the ecosystem with the largest active wallet base in the RWA sector and 200+ projects, Plume is shaping the next generation of onchain capital markets.

Learn more at https://plume.org/ 

Media Contact

Leila Stein, Content Marketing Manager, press@plumenetwork.xyz